(GSK) GlaxoSmithKline - Ratings and Ratios
Vaccines, Specialty Medicines, General Medicines
GSK EPS (Earnings per Share)
GSK Revenue
Description: GSK GlaxoSmithKline
GlaxoSmithKline PLC ADR (NYSE:GSK) is a pharmaceutical company with a diverse portfolio of vaccines, specialty medicines, and general medicines. The companys product offerings span various therapeutic areas, including oncology, respiratory diseases, HIV, and infectious diseases. GSKs vaccine portfolio includes products for diseases such as Shingles, Meningitis, and Human Papilloma Virus.
From a business perspective, GSK operates through two main segments: Commercial Operations and Total R&D. The companys research and development efforts are focused on developing innovative treatments for various diseases, including mRNA vaccines for infectious diseases through its collaboration with CureVac. With a history dating back to 1715, GSK has established itself as a major player in the pharmaceutical industry.
Key performance indicators (KPIs) that can be used to evaluate GSKs financial performance include its revenue growth, operating margin, and return on equity (RoE). With a RoE of 22.44, GSK demonstrates a strong ability to generate profits from shareholder equity. Additionally, the companys dividend yield and payout ratio can be used to assess its attractiveness to income-seeking investors. GSKs market capitalization of approximately $80 billion USD indicates its significant presence in the global pharmaceutical market.
To further analyze GSKs investment potential, one can examine its product pipeline, competitive landscape, and industry trends. The companys ability to innovate and bring new products to market, as well as its pricing power and market share, are crucial factors in determining its long-term success. By evaluating these factors, investors can gain a more comprehensive understanding of GSKs growth prospects and potential risks.
GSK Stock Overview
| Market Cap in USD | 82,104m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1986-07-09 |
GSK Stock Ratings
| Growth Rating | 55.4% |
| Fundamental | 77.9% |
| Dividend Rating | 33.4% |
| Return 12m vs S&P 500 | -16.3% |
| Analyst Rating | 2.88 of 5 |
GSK Dividends
| Dividend Yield 12m | 4.28% |
| Yield on Cost 5y | 5.43% |
| Annual Growth 5y | -5.26% |
| Payout Consistency | 91.5% |
| Payout Ratio | 38.2% |
GSK Growth Ratios
| Growth Correlation 3m | 62.3% |
| Growth Correlation 12m | 50.7% |
| Growth Correlation 5y | 53% |
| CAGR 5y | 15.40% |
| CAGR/Max DD 3y | 0.54 |
| CAGR/Mean DD 3y | 2.05 |
| Sharpe Ratio 12m | 0.91 |
| Alpha | 0.28 |
| Beta | 0.000 |
| Volatility | 21.07% |
| Current Volume | 3929.3k |
| Average Volume 20d | 3447.8k |
| Stop Loss | 39.1 (-3.1%) |
| Signal | 0.24 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (3.42b TTM) > 0 and > 6% of Revenue (6% = 1.90b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA -0.25pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -8.55% (prev -11.39%; Δ 2.84pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 7.72b > Net Income 3.42b (YES >=105%, WARN >=100%) |
| Net Debt (-3.60b) to EBITDA (8.61b) ratio: -0.42 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.06b) change vs 12m ago -0.29% (target <= -2.0% for YES) |
| Gross Margin 71.36% (prev 72.56%; Δ -1.20pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 53.92% (prev 54.16%; Δ -0.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.15 (EBITDA TTM 8.61b / Interest Expense TTM 646.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.03
| (A) -0.05 = (Total Current Assets 17.67b - Total Current Liabilities 20.38b) / Total Assets 59.26b |
| (B) 0.15 = Retained Earnings (Balance) 8.80b / Total Assets 59.26b |
| (C) 0.09 = EBIT TTM 5.27b / Avg Total Assets 58.66b |
| (D) 0.23 = Book Value of Equity 10.15b / Total Liabilities 44.90b |
| Total Rating: 1.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 77.88
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 6.47% = 3.24 |
| 3. FCF Margin 14.75% = 3.69 |
| 4. Debt/Equity 1.03 = 1.99 |
| 5. Debt/Ebitda 1.78 = 0.44 |
| 6. ROIC - WACC (= 19.66)% = 12.50 |
| 7. RoE 24.18% = 2.01 |
| 8. Rev. Trend 43.21% = 3.24 |
| 9. EPS Trend 25.44% = 1.27 |
What is the price of GSK shares?
Over the past week, the price has changed by -0.35%, over one month by +3.30%, over three months by +2.73% and over the past year by -0.83%.
Is GlaxoSmithKline a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GSK is around 41.22 USD . This means that GSK is currently overvalued and has a potential downside of 2.13%.
Is GSK a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 5
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the GSK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 39 | -3.3% |
| Analysts Target Price | 39 | -3.3% |
| ValueRay Target Price | 44.5 | 10.3% |
Last update: 2025-09-11 04:39
GSK Fundamental Data Overview
CCE Cash And Equivalents = 3.60b GBP (last quarter)
P/E Trailing = 18.287
P/E Forward = 7.8493
P/S = 2.5957
P/B = 4.1143
P/EG = 0.3551
Beta = 0.289
Revenue TTM = 31.63b GBP
EBIT TTM = 5.27b GBP
EBITDA TTM = 8.61b GBP
Long Term Debt = 15.30b GBP (from longTermDebt, last quarter)
Short Term Debt = unknown (0.0)
Debt = 15.30b GBP (Calculated: Short Term 0.0 + Long Term 15.30b)
Net Debt = -3.60b GBP (from netDebt column, last quarter)
Enterprise Value = 72.07b GBP (60.36b + Debt 15.30b - CCE 3.60b)
Interest Coverage Ratio = 8.15 (Ebit TTM 5.27b / Interest Expense TTM 646.0m)
FCF Yield = 6.47% (FCF TTM 4.67b / Enterprise Value 72.07b)
FCF Margin = 14.75% (FCF TTM 4.67b / Revenue TTM 31.63b)
Net Margin = 10.82% (Net Income TTM 3.42b / Revenue TTM 31.63b)
Gross Margin = 71.36% ((Revenue TTM 31.63b - Cost of Revenue TTM 9.06b) / Revenue TTM)
Tobins Q-Ratio = 7.10 (Enterprise Value 72.07b / Book Value Of Equity 10.15b)
Interest Expense / Debt = 1.20% (Interest Expense 184.0m / Debt 15.30b)
Taxrate = 15.13% (526.0m / 3.48b)
NOPAT = 4.47b (EBIT 5.27b * (1 - 15.13%))
Current Ratio = 0.87 (Total Current Assets 17.67b / Total Current Liabilities 20.38b)
Debt / Equity = 1.03 (Debt 15.30b / last Quarter total Stockholder Equity 14.79b)
Debt / EBITDA = 1.78 (Net Debt -3.60b / EBITDA 8.61b)
Debt / FCF = 3.28 (Debt 15.30b / FCF TTM 4.67b)
Total Stockholder Equity = 14.16b (last 4 quarters mean)
RoA = 5.78% (Net Income 3.42b, Total Assets 59.26b )
RoE = 24.18% (Net Income TTM 3.42b / Total Stockholder Equity 14.16b)
RoCE = 17.88% (Ebit 5.27b / (Equity 14.16b + L.T.Debt 15.30b))
RoIC = 24.66% (NOPAT 4.47b / Invested Capital 18.13b)
WACC = 5.01% (E(60.36b)/V(75.67b) * Re(6.02%)) + (D(15.30b)/V(75.67b) * Rd(1.20%) * (1-Tc(0.15)))
Shares Correlation 3-Years: 66.68 | Cagr: 0.05%
Discount Rate = 6.02% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 77.05% ; FCFE base≈4.69b ; Y1≈4.32b ; Y5≈3.90b
Fair Price DCF = 34.86 (DCF Value 70.18b / Shares Outstanding 2.01b; 5y FCF grow -9.75% → 3.0% )
EPS Correlation: 25.44 | EPS CAGR: 4.45% | SUE: 1.93 | # QB: 6
Revenue Correlation: 43.21 | Revenue CAGR: 0.72% | SUE: N/A | # QB: None
Additional Sources for GSK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle